|
FY2025
12 months to Dec 31, 2025
|
FY2024
1 months to Jan 31, 2025
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Amortization of right of use assets - financing | |||||
| Amortization of right of use assets - operating lease | |||||
| Compensation | |||||
| (Gain) Loss on marketable securities | |||||
| Amortization of financing fees | |||||
| Impairment and amortization of referral and support services agreement advance | |||||
| Adjustment to expected losses on accounts receivable | |||||
| Stock warrant (income) expense | |||||
| Deferred income tax expense | |||||
| Derecognition of contingency and grant | |||||
| Change in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Referral and support services agreement advance | |||||
| Prepaid expenses, other current assets and other assets | |||||
| Accounts payable | |||||
| Accrued expenses and other liabilities | |||||
| Lease liability - operating lease | |||||
| Net cash provided by/(used in) operating activities | |||||
| Investing activities: | |||||
| Purchases of equipment and capitalized development costs | |||||
| Purchase of marketable securities | |||||
| Proceeds from the sale of marketable securities | |||||
| Net cash provided by/(used in) investing activities | |||||
| Financing activities: | |||||
| Gross proceeds from line of credit | |||||
| Repayments on line of credit | |||||
| Gross proceeds from sale | |||||
| Proceeds net of payments on Financing Agreement | |||||
| Principal payments on finance lease obligations | |||||
| Net taxes paid on restricted stock unit grants exercised | |||||
| Proceeds from at-the-market sales | |||||
| Net cash provided by/(used in) financing activities | |||||
| Net change - cash | |||||
| Net change - cash | |||||
| Cash and cash equivalent, beginning of year | |||||
| Cash and cash equivalent, end of year | |||||
| Supplemental information: | |||||
| Interest paid | |||||
| Assets purchased under finance lease obligations | |||||
| Acquisition of right of use asset for operating lease liability | |||||
| Noncash investing and financing activities: | |||||
| Acquisition of right of use asset for operating lease liability | |||||
| Issuance of 3,287,537 restricted stock units to settle accrued incentive liability | |||||
Loading...